Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3
Authors' conclusion
Somapacitan showed similar efficacy and safety in patients who continued somapacitan treatment and those who switched from daily GH to somapacitan. Once-weekly injections may lead to a reduced treatment burden relative to once-daily injections. A plain-language summary of this work is available.
Study context
- Population
- Prepubertal, GH-naive children with growth hormone deficiency (GHD)50 completed 4 years
- Comparison
- Somapacitan continued vs switch from daily GH to somapacitan
- Outcome
- Main outcomes: HV, change from baseline in HV SDS and height SDS, disease burden, and treatment burden for patients and parents/guardians
- Follow-up
- 4 years
Methodological detailsmulticenter, 29 sites in 11 countries
- Multicenter
- 29 sites in 11 countries
Main finding
As reported in the abstract
Change from baseline in HV and HV SDS
- Changes from baseline in height velocity (HV) and HV SD score (SDS) were similar and as expected in both groups
Further findings
Treatment burden (observer-reported)
- Reduced treatment burden for patients and parents/guardians when switching from daily GH to somapacitan
Parent/guardian preference
- Strongly/very strongly preferred somapacitan over daily GH
- 81.8%
Original publication
Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3. J Clin Endocrinol Metab. Published 30 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →